Poland

Medical cannabis legal since 2017. Any licensed Polish physician may prescribe — no approved indication list. Health insurance (NFZ) does not reimburse cannabis except in very limited circumstances. Out-of-pocket cost is the norm for Polish patients.

Despite legal status since 2017, practical access is hampered by: poor reimbursement, limited prescriber awareness, and many pharmacies not stocking cannabis. Patients report difficulty finding pharmacies with product in stock — a well-documented supply chain gap.

URPL manages per-shipment import authorizations. Processing: 3–6 weeks — longer than most EU peers. Polish-language labeling is mandatory and a common deficiency. Individual Import Authorization (IIA) is the most common pathway for unregistered products.

~38 million population — EU's fifth largest. As reimbursement and access improve, Poland has significant potential. Several international cannabis companies view Poland as a priority emerging EU market.

Poland has no significant domestic cannabis production for medical use — it is a pure importing market. Primary suppliers are Germany, Netherlands, Israel, and Canada.

Per-shipment authorization from URPL. Processing: 3–6 weeks for complete applications. Must include EU-GMP and GACP certificates, COA per batch, exporting country authorization, and Polish-language labeling plan.

For unregistered products, the prescribing physician applies to URPL for an IIA per patient. Processing: 30–60 days. Valid for one patient and defined quantity. Most common pathway for foreign cannabis products entering Poland.

URPL requires Polish-language product labeling and a Polish-language summary of product characteristics. Certified Polish translations of key documents may be required. This is the most commonly flagged deficiency in URPL applications.

Primary air entry point for pharmaceutical imports. EU customs narcotic declaration under Single Convention 1961. Standard EU customs procedures.

All finished medicinal cannabis imported into Poland requires EU-GMP Part I. Certificate from EEA or PIC/S authority with cannabis scope required. URPL rejects applications with expired or out-of-scope certificates.

EU QP named on Polish importer's URPL wholesale authorization certifies each batch. English-language batch certificates and COAs are accepted — Polish language not required for GMP documentation.

URPL participates in the EU GMP inspection network. All EEA national authority certificates (ANSM, IMB, BfArM etc.) and PIC/S certificates (IMFA, TGA, Health Canada, MHRA) are accepted without URPL re-inspection.

ISO 17065-accredited third-party certification required. Current certificate at time of URPL import authorization application. 1–3 year validity. No grace period. Chain of custody from cultivation to finished product must be documented.